Cellectis held its Business update call on September 14, giving investors access to English- and French-language webcasts. The event matters because the company said it would provide a business update, while a replay is available following the event for investors reviewing Cellectis’ latest information.

Key Highlights

  • Cellectis announced that it will host a business update call and webcast on September 14, 2026.
  • The announcement included English-language and French-language sessions at different times.
  • A replay will be available on Cellectis’ website following the event.

Cellectis S.A. (NASDAQ: CLLS) announced that it will host a business update call and webcast on September 14, 2026. The event will provide a business update through conference-call and webcast formats.

Cellectis also announced conference-call access for participants, including toll-free numbers for France. The update will be presented through English-language and French-language sessions.

Cellectis Describes Its Gene-Editing Platform

Cellectis describes itself as a clinical-stage biotechnology company developing cell and gene therapies through its gene-editing platform. Its work includes an allogeneic approach to CAR T immunotherapies in oncology and gene therapies for other therapeutic indications.